Remove 2023 Remove Compounding Remove Dosage
article thumbnail

TikTok Videos on IBD Provide Low Quality Information

Drug Topics

Updated 2023 Aug 4]. link] Recent Videos Related Content FDA Grants Expanded Interchangeability Designation to Yuflyma Ashley Gallagher May 23rd 2025 Article Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

FDA 281
article thumbnail

Technology advancement driving growth of rapid sterility testing market

European Pharmaceutical Review

billion in 2023 to $4.3 It is expected hold a compound annual growth rate (CAGR) of 8.20 percent between 2023 and 2032. Furthermore, an increasing demand for the previously mentioned dosage forms is a key factor contributing to the expansion of the market. billion by 2032.

Dosage 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Automation to accelerate biopharma in next decade

European Pharmaceutical Review

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 percent during the forecast period 2023-2033. million in 2023, according to the data. The market’s overall world revenue value will exceed $1,855.0

Dosage 98
article thumbnail

France gets new sterile liquid drug manufacturing facility

European Pharmaceutical Review

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). The site will have approximately 100 employees and create 50 new jobs throughout 2023.

article thumbnail

3D printing and personalised medicines: embracing innovative technologies

Hospital Pharmacy Europe

Supporting the successful compounding of drugs with 3D printing processes has the potential to not only fulfil unmet patient needs but also drive efficiencies in hospital pharmacies. These products require a high degree of adaptability, particularly in terms of dosage, to meet patients’ needs.

Hospitals 111
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmTech

Related Content Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia Patrick Lavery June 9th 2025 Article The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Dosage 52